Clinical Perspective
The CagriSema Phase 3 program demonstrates record-breaking efficacy in obesity pharmacotherapy through dual-pathway modulation. By combining GLP-1 receptor agonism (semaglutide) with amylin analog activity (cagrilintide), CagriSema achieved 22.7% weight loss in obesity—matching or exceeding injectable GLP-1/GIP agonists like tirzepatide. This positions CagriSema as a potential best-in-class obesity medication, pending FDA review expected in Q1 2026.
Summary
Overview
Novo Nordisk designed parallel late-stage trials to answer two critical questions:
Can a dual GLP-1/amylin combination achieve superior weight loss vs single agents?
Can CagriSema deliver meaningful weight loss and glycemic control in type 2 diabetes?
Development History
CagriSema's path from early safety studies to pivotal Phase 3 trials
Obesity Trial
- 22.7% weight loss (CagriSema) vs 16.1% (semaglutide alone) vs 11.8% (cagrilintide alone) over 68 weeks
- 60% achieved ≥20% weight loss
- 40.4% achieved ≥25% weight loss
- N=3,417 participants
First obesity medication to demonstrate true synergy between GLP-1 and amylin pathways. Results match or exceed tirzepatide (20.9%), positioning CagriSema as a potential best-in-class obesity medication targeting complementary appetite and satiety mechanisms.
Part of multi-trial Phase 3 program supporting FDA filing in Q1 2026. If approved in late 2026/early 2027, will compete directly with Zepbound and may offer superior efficacy through dual-pathway modulation.
- BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidity
- Ages 18-75 years
- No type 2 diabetes diagnosis
- Stable weight (±5 kg) for 90 days prior to screening
- Type 2 diabetes or HbA1c ≥6.5%
- Prior GLP-1 receptor agonist use within 90 days
- Bariatric surgery within 1 year
REDEFINE 1 evaluated the fixed-dose combination against each component alone and placebo, revealing true pharmacological synergy:[1]
Study Arms
- CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) → −22.7% weight loss
- Semaglutide 2.4mg alone → −16.1% weight loss
- Cagrilintide 2.4mg alone → −11.8% weight loss
- Placebo → −2.3% weight loss
Dose Escalation Protocol: All participants titrated from lower doses over 20 weeks to minimize GI side effects, reaching target dose at Week 20. This gradual titration is critical for tolerability.
The combination's 22.7% efficacy significantly exceeds the additive effect of individual components, demonstrating true synergy through complementary GLP-1 and amylin receptor pathways.
- ≥20% weight loss: 60% of participants on CagriSema vs 16.2% semaglutide alone
- ≥25% weight loss: 40.4% on CagriSema vs 16.2% semaglutide alone vs 0.9% placebo—unprecedented proportion achieving this threshold
- BMI < 30 (overweight threshold): 50.7% achieved vs 10.2% placebo—more than half normalized BMI category
- Weight loss trajectory: Losses progressed through Week 68 with continued efficacy, suggesting potential for further benefit with extended treatment.[1]
Analysis of treatment effects across patient subgroups demonstrated consistent efficacy regardless of baseline characteristics:[1]
- By Sex: CagriSema demonstrated robust efficacy in both male and female participants, with no significant sex-based differences in weight loss magnitude.
- By Age: Weight loss was consistent across all age groups (18-75 years), indicating age does not significantly affect treatment response.
- By Baseline BMI: Efficacy maintained across BMI categories, though participants with higher baseline BMI showed greater absolute kilogram loss.
- By Race/Ethnicity: Treatment effects consistent across racial and ethnic groups, with no treatment-by-subgroup interactions observed.
Clinical Implication: The broad efficacy across demographic subgroups reinforces CagriSema's position as a universally effective obesity medication for diverse patient populations.
| Characteristic | CagriSema 2.4mg/2.4mg | Semaglutide 2.4mg | Cagrilintide 2.4mg | Placebo |
|---|---|---|---|---|
| N | 2,108 | 302 | 302 | 705 |
| Mean Age | 48.2 yrs | 47.9 yrs | 48.5 yrs | 48.1 yrs |
| Female | 73% | 72% | 74% | 73% |
| Mean BMI | 38.2 kg/m² | 38.1 kg/m² | 38.3 kg/m² | 38.0 kg/m² |
| Mean Weight | 106.9 kg | 106.5 kg | 107.2 kg | 106.6 kg |
| Prediabetes | 41% | 42% | 40% | 41% |
| Hypertension | 49% | 48% | 50% | 49% |
Large, representative cohort with predominantly female enrollment and multiple metabolic comorbidities—typical of obesity trial populations.
| Endpoint | CagriSema 2.4mg/2.4mg | Semaglutide 2.4mg | Cagrilintide 2.4mg | Placebo | p-value |
|---|---|---|---|---|---|
| Waist circumference | −14.2 cm | −10.4 cm | −7.8 cm | −3.3 cm | < 0.001 |
| Systolic BP | −10.9 mmHg | −8.3 mmHg | −5.4 mmHg | −2.1 mmHg | < 0.001 |
| Fasting glucose | −9.8 mg/dL | −7.2 mg/dL | −4.1 mg/dL | −1.5 mg/dL | < 0.001 |
| HbA1c (prediabetes) | −0.52% | −0.38% | −0.21% | −0.08% | < 0.001 |
| Triglycerides | −25% | −19% | −12% | −3% | < 0.001 |
| Non-HDL cholesterol | −11.2% | −8.4% | −4.7% | −1.2% | < 0.001 |
| C-reactive protein | −52% | −41% | −28% | −8% | < 0.001 |
| Prediabetes normalization | 87.7% | 72.3% | 48.1% | 22.4% | < 0.001 |
Results demonstrate broad cardiometabolic benefits across all measured endpoints, with CagriSema showing consistent superiority over individual components.
REDEFINE 1 establishes CagriSema as the first obesity medication to demonstrate true synergy between GLP-1 and amylin pathways, achieving 22.7% weight loss—matching or exceeding tirzepatide's 20.9%. The 40.4% of participants achieving ≥25% weight loss is unprecedented in obesity pharmacotherapy. By targeting complementary receptors (GLP-1 in arcuate nucleus, amylin in area postrema), CagriSema provides additive satiety signaling through distinct neural pathways. This positions CagriSema as a potential best-in-class obesity medication, pending regulatory approval.
Type 2 Diabetes Trial
- 15.7% weight loss in type 2 diabetes patients vs 3.4% placebo
- 73.5% achieved HbA1c ≤6.5% (near-normal) vs 15.9% placebo
- Mean HbA1c reduction: −2.2% vs −0.4% placebo
- N=1,206 participants
First medication to demonstrate both exceptional weight loss (15.7%) and near-normal glycemic control (73.5% achieving HbA1c ≤6.5%) in type 2 diabetes. The dual benefit addresses the core pathophysiology of diabesity—insulin resistance driven by excess adiposity.
Supports dual-indication filing (obesity + type 2 diabetes) in Q1 2026. If approved, will offer a single medication addressing both weight and glycemic control without need for additional diabetes medications in many patients.
- Type 2 diabetes ≥180 days
- HbA1c 7.0–10.0% on current therapy
- BMI ≥ 27 kg/m²
- On stable metformin dose (≥1500 mg/day or max tolerated)
- Ages 18-75 years
- Type 1 diabetes or secondary diabetes
- GLP-1 receptor agonist use within 90 days
- Insulin use (except short-term for acute illness)
- eGFR < 30 mL/min/1.73m²
REDEFINE 2 evaluated CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) versus placebo in patients with type 2 diabetes, with all participants continuing their background diabetes medications:[2]
Study Arms
- CagriSema (2.4mg/2.4mg) → −15.7% weight loss, −2.2% HbA1c
- Placebo → −3.4% weight loss, −0.4% HbA1c
Background Therapy: 100% on metformin, 32% on SGLT2 inhibitors, 18% on sulfonylureas. CagriSema effects were incremental to background therapy.
The substantial glycemic benefit (73.5% achieving near-normal HbA1c) suggests many patients may de-escalate or discontinue other diabetes medications under medical supervision.
- HbA1c ≤6.5% (near-normal): 73.5% achieved vs 15.9% placebo—nearly 5x as many participants normalized blood sugar
- HbA1c < 7% (ADA target): 86.4% achieved vs 35.7% placebo
- ≥10% weight loss: 68.9% vs 13.2% placebo
- ≥15% weight loss: 55.7% vs 4.8% placebo
- Clinical Implication: The high proportion achieving near-normal glycemic control without hypoglycemia represents a paradigm shift in type 2 diabetes management—addressing root cause (excess adiposity) rather than just symptoms.[2]
Treatment effects were evaluated across key patient subgroups to assess consistency of dual metabolic benefits:[2]
- By Baseline HbA1c: CagriSema demonstrated robust glycemic improvement regardless of baseline control. Patients with HbA1c ≥9% showed particularly dramatic reductions (−3.5%), though significant benefits seen even in well-controlled patients (HbA1c 7-8%).
- By Diabetes Duration: Benefits consistent whether diabetes was recent (<5 years) or longstanding (>10 years), suggesting efficacy across disease stages.
- By Baseline BMI: Weight loss proportional across BMI categories, with higher BMI patients achieving greater absolute kilogram reductions.
- By Background Therapy: CagriSema's benefits additive to metformin, SGLT2 inhibitors, and sulfonylureas, though hypoglycemia risk modestly higher with sulfonylureas (dose reduction advised).
Clinical Implication: The consistent dual benefits across subgroups reinforce CagriSema's broad applicability in type 2 diabetes with obesity/overweight, regardless of baseline characteristics or background therapy.
| Characteristic | CagriSema 2.4mg/2.4mg | Placebo |
|---|---|---|
| N | 904 | 302 |
| Mean Age | 56.4 yrs | 56.8 yrs |
| Female | 52% | 51% |
| Mean BMI | 36.1 kg/m² | 36.0 kg/m² |
| Mean Weight | 101.3 kg | 101.1 kg |
| Mean Baseline HbA1c | 8.3% | 8.4% |
| Mean T2D Duration | 8.9 years | 9.1 years |
| On Metformin Only | 68% | 67% |
| On Metformin + SGLT2i | 32% | 33% |
Typical type 2 diabetes population with moderate glycemic dyscontrol and obesity, representative of primary care patients.
| Endpoint | CagriSema 2.4mg/2.4mg | Placebo | p-value |
|---|---|---|---|
| HbA1c ≤6.5% (near-normal) | 73.5% | 15.9% | < 0.001 |
| HbA1c < 7.0% (target) | 86.4% | 35.7% | < 0.001 |
| Fasting glucose | −68 mg/dL | −15 mg/dL | < 0.001 |
| Systolic BP | −9.3 mmHg | −2.7 mmHg | < 0.001 |
| Triglycerides | −29% | −7% | < 0.001 |
| Waist circumference | −11.8 cm | −3.9 cm | < 0.001 |
| Severe hypoglycemia | 0.8% | 0.3% | 0.32 |
Nearly 3/4 of participants achieved near-normal blood sugar (HbA1c ≤6.5%) without significant hypoglycemia risk. Broad cardiometabolic benefits across all endpoints.
REDEFINE 2 demonstrates CagriSema's unique dual metabolic benefit in type 2 diabetes: exceptional weight loss (15.7%) combined with near-normalization of blood sugar (73.5% achieving HbA1c ≤6.5%). This represents a paradigm shift from traditional diabetes management (treating hyperglycemia with medications that often cause weight gain) to addressing the root pathophysiology—excess adiposity driving insulin resistance. The low hypoglycemia rate (despite profound glycemic improvement) reflects GLP-1's glucose-dependent mechanism. CagriSema may enable many patients to achieve disease remission or substantial medication de-escalation.
Safety
Adverse Events
| Adverse Event | CagriSema (%) | Comparator | Note |
|---|---|---|---|
| Nausea | 55 | Placebo 18 / Semaglutide 44 | Mostly mild to moderate |
| Constipation | 32 | Placebo 12 / Semaglutide 24 | Transient |
| Vomiting | 28 | Placebo 6 / Semaglutide 19 | During titration |
| Diarrhea | 24 | Placebo 11 / Semaglutide 31 | Self-limited |
| Dyspepsia | 12 | < 10 | Mild |
Discontinuation Due to Adverse Events: 6.0% (CagriSema) vs 3.7% (placebo). Most discontinuations occurred during dose escalation phase.[1]
Serious Adverse Events: Low (4.8%) and balanced between groups. No pancreatitis, thyroid carcinoma, or cardiovascular safety signals detected. Hypoglycemia rare in obesity trial (no background diabetes medications). In REDEFINE 2 (diabetes trial), severe hypoglycemia was low (0.8%) and similar to placebo (0.3%).[1,2]
Access
Trial Status
- REDEFINE 1 and REDEFINE 2 completed (December 2024)
- Results published in New England Journal of Medicine (June 2025)
- FDA filing anticipated Q1 2026
- Additional REDEFINE trials (cardiovascular outcomes, other indications) ongoing
Participation Opportunities
To check active CagriSema studies:
- Visit ClinicalTrials.gov
- Search "CagriSema" or "cagrilintide semaglutide"
- Filter for "Recruiting" or "Not yet recruiting"
- Discuss eligibility with a qualified healthcare provider
FAQs
REDEFINE 1 showed 22.7% weight loss at 68 weeks in obesity; REDEFINE 2 showed 15.7% weight loss + 73.5% achieving HbA1c ≤6.5% in type 2 diabetes—both superior to comparators.
No. FDA submission is planned for Q1 2026, with approval anticipated in late 2026 or early 2027.
CagriSema achieved 22.7% weight loss in obesity trials, compared to tirzepatide's 20.9% in SURMOUNT-1. While both are highly effective, CagriSema works through GLP-1 + amylin pathways vs tirzepatide's GLP-1 + GIP pathways.
CagriSema combines semaglutide 2.4mg with cagrilintide 2.4mg (an amylin analog). The combination achieved 22.7% weight loss vs 16.1% with semaglutide alone—demonstrating true synergy through dual GLP-1 and amylin receptor activation targeting complementary satiety pathways in the brain.
Gastrointestinal effects such as nausea (55%), constipation (32%), and vomiting (28%), mainly during dose escalation. Most are mild to moderate and improve over time. Discontinuation rate was 6% vs 3.7% placebo.
Main Phase 3 studies (REDEFINE 1 & 2) are complete. Check ClinicalTrials.gov for extension studies, cardiovascular outcomes trials, or other REDEFINE program trials that may be recruiting.
Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. While GLP-1 acts primarily on receptors in the arcuate nucleus (hypothalamus), amylin acts on area postrema and other brainstem regions. By targeting both pathways simultaneously, CagriSema provides complementary and synergistic appetite suppression through distinct neural circuits—explaining why the combination (22.7%) significantly exceeds either component alone.
Yes, all primary endpoints in both REDEFINE 1 and REDEFINE 2 achieved high statistical significance (p < 0.001). This means there is less than a 0.1% probability that the results occurred by chance. The large sample sizes (3,417 in REDEFINE 1, 1,206 in REDEFINE 2) and robust effect sizes provide very high confidence in CagriSema's efficacy.
Citations
- [1]Knop FK, Aronne LJ, Barros D, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;392(24):2265-2277. doi:10.1056/NEJMoa2502081View source →
- [2]Frias JP, Deenadayalan S, Erichsen L, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;392(24):2278-2289. doi:10.1056/NEJMoa2502082View source →
- [3]ClinicalTrials.gov. Effect and Safety of Cagrilintide + Semaglutide Versus Placebo in People Living With Overweight or Obesity (REDEFINE 1). NCT05567796.View source →
- [4]ClinicalTrials.gov. Research Study to Look at How Well CagriSema Works in People Living With Type 2 Diabetes and Overweight or Obesity (REDEFINE 2). NCT05394519.View source →
- [5]Novo Nordisk A/S. CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. Press Release, December 20, 2024.View source →
- [6]Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.View source →
- [7]Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.View source →
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.